Clusterin in neurological disorders: Molecular perspectives and clinical relevance

Brain Research Bulletin

Volumn 88, Issue 5, 2012, Pages 434-443

  Charnay, Yves ^a   Imhof, Anouk ^c   Vallet, Philippe G ^a   Kovari, Eniko ^a   Bouras, Constantin ^a   Giannakopoulos, Panteleimon ^a,b  

^a Department of Mental Health and Psychiatry   (Switzerland)

^b University of Lausanne Medical Center   (Switzerland)

^c Clinical Outpatient Service of Geneva State   (Switzerland)

Author keywords

Apolipoprotein J; Brain stroke; Dorsal root ganglia; Motor nuclei; Neurodegenerative diseases; Retina; Secreted clusterin

Indexed keywords

AMYLOID BETA PROTEIN[1-40]; CLUSTERIN; MESSENGER RNA; PRION PROTEIN; PROTEIN KINASE B; TRANSFORMING GROWTH FACTOR BETA;

AGING; ALZHEIMER DISEASE; BLOOD BRAIN BARRIER; BRAIN DEVELOPMENT; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; BRAIN LEVEL; CELL SUBPOPULATION; CELL SURVIVAL; COGNITION; DEGENERATIVE DISEASE; DISEASE ASSOCIATION; HOMOZYGOTE; IMMUNOREACTIVITY; MACROGLIA; MOLECULAR MECHANICS; MULTIPLE SCLEROSIS; NERVE CELL PLASTICITY; NERVE FIBER GROWTH; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRION DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FOLDING; RETINOPATHY; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPINAL GANGLION; TRAUMATIC BRAIN INJURY;

ANIMALS; CLUSTERIN; GENE EXPRESSION REGULATION; HUMANS; MOLECULAR TARGETED THERAPY; NERVOUS SYSTEM DISEASES; NEUROPROTECTIVE AGENTS;

EID: 84862508940     PISSN: 03619230     EISSN: 18732747     Source Type: Journal    
DOI: 10.1016/j.brainresbull.2012.05.006     Document Type: Review

References (177)

1. Ahuja H.S., Tenniswood M., Lockshin R., Zakeri Z.F. Expression of clusterin in cell differentiation and cell death. Biochemistry and Cell Biology 1994, 72:523-530.
2. An E., Lu X., Flippin J., Devaney J.M., Halligan B., Hoffman E.P., Strunnikova N., Csaky K., Hathout Y. Secreted proteome profiling in human RPE cell cultures derived from donors with age related macular degeneration and age matched healthy donors. Journal of Proteome Research 2006, 5:2599-2610.
3. Anderson A.J., Najbauer J., Huang W., Young W., Robert S. Upregulation of complement inhibitors in association with vulnerable cells following contusion-induced spinal cord injury. Journal of Neurotrauma 2005, 22:382-397.
4. Antonelou M.H., Kriebardis A.G., Stamoulis K.E., Trougakos I.P., Papassideri I.S. Apolipoprotein J/clusterin is a novel structural component of human erythrocytes and a biomarker of cellular stress and senescence. PLoS One 2011, 6:e26032.
5. Aronow B.J., Lund S.D., Brown T.L., Harmony J.A., Witte D.P., Apolipoprotein J. expression at fluid-tissue interfaces: potential role in barrier cytoprotection. Proceedings of the National Academy of Sciences of the United States of America 1993, 90:725-729.
6. Arumugam T.V., Woodruff T.M., Lathia J.D., Selvaraj P.K., Mattson M.P., Taylor S.M. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience 2009, 158:1074-1089.
7. Atkinson C., Varela J.C., Tomlinson S. Complement-dependent inflammation and injury in a murine model of brain dead donor hearts. Circulation Research 2009, 105:1094-1101.
8. Bajari T.M., Strasser V., Nimpf J., Schneider W.J. A model for modulation of leptin activity by association with clusterin. FASEB Journal: Official Publication of the Federation of American Societies for Experimental Biology 2003, 17:1505-1507.
9. Balantinou E., Trougakos I.P., Chondrogianni N., Margaritis L.H., Gonos E.S. Transcriptional and posttranslational regulation of clusterin by the two main cellular proteolytic pathways. Free Radical Biology & Medicine 2009, 46:1267-1274.
10. Bartl M.M., Luckenbach T., Bergner O., Ullrich O., Koch-Brandt C. Multiple receptors mediate apoJ-dependent clearance of cellular debris into nonprofessional phagocytes. Experimental Cell Research 2001, 271:130-141.
11. Bell R.D., Sagare A.P., Friedman A.E., Bedi G.S., Holtzman D.M., Deane R., Zlokovic B.V. Transport pathways for clearance of human Alzheimer's amyloid beta-peptide and apolipoproteins E and J in the mouse central nervous system. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 2007, 27:909-918.
12. Bellander B.M., Singhrao S.K., Ohlsson M., Mattsson P., Svensson M. Complement activation in the human brain after traumatic head injury. Journal of Neurotrauma 2001, 18:1295-1311.
13. Bettens K., Brouwers N., Engelborghs S., Lambert J.C., Rogaeva E., Vandenberghe R., Le Bastard N., Pasquier F., Vermeulen S., Van Dongen J., Mattheijssens M., Peeters K., Mayeux R., St George-Hyslop P., Amouyel P., De Deyn P.P., Sleegers K., Van Broeckhoven C. Both common variations and rare non-synonymous substitutions and small insertion/deletions in CLU are associated with increased Alzheimer risk. Molecular Neurodegeneration 2012, 7:3.
14. Bettuzzi S., Rizzi F. Chapter 5: nuclear CLU (nCLU) and the fate of the cell. Advances in Cancer Research 2009, 104:59-88.
15. Bhutia S.K., Das S.K., Kegelman T.P., Azab B., Dash R., Su Z.Z., Wang X.Y., Rizzi F., Bettuzzi S., Lee S.G., Dent P., Grant S., Curiel D.T., Sarkar D., Fisher P.B. mda-7/IL-24 differentially regulates soluble and nuclear clusterin in prostate cancer. Journal of Cellular Physiology 2012, 227:1805-1813.
16. Blaschuk O., Burdzy K., Fritz I.B. Purification and characterization of a cell-aggregating factor (clusterin), the major glycoprotein in ram rete testis fluid. The Journal of Biological Chemistry 1983, 258:7714-7720.
17. Braskie M.N., Jahanshad N., Stein J.L., Barysheva M., McMahon K.L., de Zubicaray G.I., Martin N.G., Wright M.J., Ringman J.M., Toga A.W., Thompson P.M. Common Alzheimer's disease risk variant within the CLU gene affects white matter microstructure in young adults. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2011, 31:6764-6770.
18. Caccamo A.E., Scaltriti M., Caporali A., D'Arca D., Scorcioni F., Candiano G., Mangiola M., Bettuzzi S. Nuclear translocation of a clusterin isoform is associated with induction of anoikis in SV40-immortalized human prostate epithelial cells. Annals of the New York Academy of Sciences 2003, 1010:514-519.
19. Calero M., Rostagno A., Frangione B., Ghiso J. Clusterin and Alzheimer's disease. Sub-cellular Biochemistry 2005, 38:273-298.
20. Carrasquillo M.M., Belbin O., Hunter T.A., Ma L., Bisceglio G.D., Zou F., Crook J.E., Pankratz V.S., Dickson D.W., Graff-Radford N.R., Petersen R.C., Morgan K., Younkin S.G. Replication of CLU, CR1, and PICALM associations with Alzheimer disease. Archives of Neurology 2010, 67:961-964.
21. Charnay Y., Imhof A., Vallet P.G., Hakkoum D., Lathuiliere A., Poku N., Aronow B., Kovari E., Bouras C., Giannakopoulos P. Clusterin expression during fetal and postnatal CNS development in mouse. Neuroscience 2008, 155:714-724.
22. Chauhan A.K., Moore T.L. Presence of plasma complement regulatory proteins clusterin (Apo J) and vitronectin (S40) on circulating immune complexes (CIC). Clinical and Experimental Immunology 2006, 145:398-406.
23. Chia S., Dent S., Ellard S., Ellis P.M., Vandenberg T., Gelmon K., Powers J., Walsh W., Seymour L., Eisenhauer E.A. Phase II trial of OGX-011 in combination with docetaxel in metastatic breast cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:708-713.
24. Chiesa R., Angeretti N., Lucca E., Salmona M., Tagliavini F., Bugiani O., Forloni G. Clusterin (SGP-2) induction in rat astroglial cells exposed to prion protein fragment 106-126. The European Journal of Neuroscience 1996, 8:589-597.
25. Choi-Miura N.H., Ihara Y., Fukuchi K., Takeda M., Nakano Y., Tobe T., Tomita M. SP-40,40 is a constituent of Alzheimer's amyloid. Acta Neuropathologica 1992, 83:260-264.
26. Cordero-Llana O., Scott S.A., Maslen S.L., Anderson J.M., Boyle J., Chowhdury R.R., Tyers P., Barker R.A., Kelly C.M., Rosser A.E., Stephens E., Chandran S., Caldwell M.A. Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells. Cell Death and Differentiation 2011, 18:907-913.
27. Corneveaux J.J., Myers A.J., Allen A.N., Pruzin J.J., Ramirez M., Engel A., Nalls M.A., Chen K., Lee W., Chewning K., Villa S.E., Meechoovet H.B., Gerber J.D., Frost D., Benson H.L., O'Reilly S., Chibnik L.B., Shulman J.M., Singleton A.B., Craig D.W., Van Keuren-Jensen K.R., Dunckley T., Bennett D.A., De Jager P.L., Heward C., Hardy J., Reiman E.M., Huentelman M.J. Association of CR1, CLU and PICALM with Alzheimer's disease in a cohort of clinically characterized and neuropathologically verified individuals. Human Molecular Genetics 2010, 19:3295-3301.
28. Crabb J.W., Miyagi M., Gu X., Shadrach K., West K.A., Sakaguchi H., Kamei M., Hasan A., Yan L., Rayborn M.E., Salomon R.G., Hollyfield J.G. Drusen proteome analysis: an approach to the etiology of age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2002, 99:14682-14687.
29. Daimon M., Oizumi T., Karasawa S., Kaino W., Takase K., Tada K., Jimbu Y., Wada K., Kameda W., Susa S., Muramatsu M., Kubota I., Kawata S., Kato T. Association of the clusterin gene polymorphisms with type 2 diabetes mellitus. Metabolism: Clinical and Experimental 2011, 60:815-822.
30. Danik M., Chabot J.G., Hassan-Gonzalez D., Suh M., Quirion R. Localization of sulfated glycoprotein-2/clusterin mRNA in the rat brain by in situ hybridization. The Journal of Comparative Neurology 1993, 334:209-227.
31. Dati G., Quattrini A., Bernasconi L., Malaguti M.C., Antonsson B., Nicoletti F., Alliod C., Di Marco R., Sagot Y., Vitte P.A., Hiver A., Greco B., Roach A., Zaratin P.F. Beneficial effects of r-h-CLU on disease severity in different animal models of peripheral neuropathies. Journal of Neuroimmunology 2007, 190:8-17.
32. de Silva H.V., Harmony J.A., Stuart W.D., Gil C.M., Robbins J. Apolipoprotein J: structure and tissue distribution. Biochemistry 1990, 29:5380-5389.
33. de Silva H.V., Stuart W.D., Duvic C.R., Wetterau J.R., Ray M.J., Ferguson D.G., Albers H.W., Smith W.R., Harmony J.A. A 70-kDa apolipoprotein designated ApoJ is a marker for subclasses of human plasma high density lipoproteins. The Journal of Biological Chemistry 1990, 265:13240-13247.
34. Dews M., Fox J.L., Hultine S., Sundaram P., Wang W., Liu Y.Y., Furth E., Enders G.H., El-Deiry W., Schelter J.M., Cleary M.A., Thomas-Tikhonenko A. The myc-miR-17-92 axis blunts TGFβ signaling and production of multiple TGFβ-dependent antiangiogenic factors. Cancer Research 2010, 70:8233-8246.
35. Dota A., Nishida K., Quantock A.J., Kinoshita S. Clusterin in human corneal endothelium and aqueous humor. Experimental Eye Research 1999, 69:705-708.
36. Ducruet A.F., Zacharia B.E., Hickman Z.L., Grobelny B.T., Yeh M.L., Sosunov S.A., Connolly E.S. The complement cascade as a therapeutic target in intracerebral hemorrhage. Experimental Neurology 2009, 219:398-403.
37. Ecroyd H., Belghazi M., Dacheux J.L., Gatti J.L. The epididymal soluble prion protein forms a high-molecular-mass complex in association with hydrophobic proteins. The Biochemical Journal 2005, 392:211-219.
38. Ekici A.I., Eren B., Turkmen N., Comunoglu N., Fedakar R. Clusterin expression in non-neoplastic adenohypophyses and pituitary adenomas: cytoplasmic clusterin localization in adenohypophysis is related to aging. Endocrine Pathology 2008, 19:47-53.
39. Erk S., Meyer-Lindenberg A., Opitz von Boberfeld C., Esslinger C., Schnell K., Kirsch P., Mattheisen M., Muhleisen T.W., Cichon S., Witt S.H., Rietschel M., Nothen M.M., Walter H. Hippocampal function in healthy carriers of the CLU Alzheimer's disease risk variant. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2011, 31:18180-18184.
40. R. Ferrari, J.H. Moreno, A.T. Minhajuddin, S.E. O'Bryant, J.S. Reisch, R.C. Barber, P. Momeni, Implication of common and disease specific variants in CLU, CR1, and PICALM, Neurobiology of Aging (2012), in press.
41. Freixes M., Puig B., Rodriguez A., Torrejon-Escribano B., Blanco R., Ferrer I. Clusterin solubility and aggregation in Creutzfeldt-Jakob disease. Acta Neuropathologica 2004, 108:295-301.
42. Gao J., Huang X., Park Y., Hollenbeck A., Chen H. An exploratory study on CLU, CR1 and PICALM and Parkinson disease. PLoS One 2011, 6:e24211.
43. Garden G.A., Bothwell M., Rubel E.W. Lack of correspondence between mRNA expression for a putative cell death molecule (SGP-2) and neuronal cell death in the central nervous system. Journal of Neurobiology 1991, 22:590-604.
44. Giannakopoulos P., Kovari E., French L.E., Viard I., Hof P.R., Bouras C. Possible neuroprotective role of clusterin in Alzheimer's disease: a quantitative immunocytochemical study. Acta Neuropathologica 1998, 95:387-394.
45. Gibson C.L., Murphy S.P. Benefits of histone deacetylase inhibitors for acute brain injury: a systematic review of animal studies. Journal of Neurochemistry 2010, 115:806-813.
46. Gnatenko D.V., Dunn J.J., McCorkle S.R., Weissmann D., Perrotta P.L., Bahou W.F. Transcript profiling of human platelets using microarray and serial analysis of gene expression. Blood 2003, 101:2285-2293.
47. Gong Y., Xi G., Wan S., Gu Y., Keep R.F., Hua Y. Effects of aging on complement activation and neutrophil infiltration after intracerebral hemorrhage. Acta Neurochirurgica. Supplement 2008, 105:67-70.
48. Griswold M.D., Roberts K., Bishop P. Purification and characterization of a sulfated glycoprotein secreted by Sertoli cells. Biochemistry 1986, 25:7265-7270.
49. Gu H., Wei X., Chen S., Kurz A., Muller U., Gasser T., Dodel R.C., Farlow M.R., Du Y. Association of clusterin gene polymorphisms with late-onset Alzheimer's disease. Dementia and Geriatric Cognitive Disorders 2011, 32:198-201.
50. Gwon J.S., Kim I.B., Lee M.Y., Oh S.J., Chun M.H. Expression of clusterin in Muller cells of the rat retina after pressure-induced ischemia. Glia 2004, 47:35-45.
51. Han B.H., DeMattos R.B., Dugan L.L., Kim-Han J.S., Brendza R.P., Fryer J.D., Kierson M., Cirrito J., Quick K., Harmony J.A., Aronow B.J., Holtzman D.M. Clusterin contributes to caspase-3-independent brain injury following neonatal hypoxia-ischemia. Nature Medicine 2001, 7:338-343.
52. Harhausen D., Khojasteh U., Stahel P.F., Morgan B.P., Nietfeld W., Dirnagl U., Trendelenburg G. Membrane attack complex inhibitor CD59a protects against focal cerebral ischemia in mice. Journal of Neuroinflammation 2010, 7:15.
53. Harold D., Abraham R., Hollingworth P., Sims R., Gerrish A., Hamshere M.L., Pahwa J.S., Moskvina V., Dowzell K., Williams A., Jones N., Thomas C., Stretton A., Morgan A.R., Lovestone S., Powell J., Proitsi P., Lupton M.K., Brayne C., Rubinsztein D.C., Gill M., Lawlor B., Lynch A., Morgan K., Brown K.S., Passmore P.A., Craig D., McGuinness B., Todd S., Holmes C., Mann D., Smith A.D., Love S., Kehoe P.G., Hardy J., Mead S., Fox N., Rossor M., Collinge J., Maier W., Jessen F., Schurmann B., van den Bussche H., Heuser I., Kornhuber J., Wiltfang J., Dichgans M., Frolich L., Hampel H., Hull M., Rujescu D., Goate A.M., Kauwe J.S., Cruchaga C., Nowotny P., Morris J.C., Mayo K., Sleegers K., Bettens K., Engelborghs S., De Deyn P.P., Van Broeckhoven C., Livingston G., Bass N.J., Gurling H., McQuillin A., Gwilliam R., Deloukas P., Al-Chalabi A., Shaw C.E., Tsolaki M., Singleton A.B., Guerreiro R., Muhleisen T.W., Nothen M.M., Moebus S., Jockel K.H., Klopp N., Wichmann H.E., Carrasquillo M.M., Pankratz V.S., Younkin S.G., Holmans P.A., O'Donovan M., Owen M.J., Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nature Genetics 2009, 41:1088-1093.
54. Harr S.D., Uint L., Hollister R., Hyman B.T., Mendez A.J. Brain expression of apolipoproteins E, J, and A-I in Alzheimer's disease. Journal of Neurochemistry 1996, 66:2429-2435.
55. Hassan M.K., Watari H., Han Y., Mitamura T., Hosaka M., Wang L., Tanaka S., Sakuragi N. Clusterin is a potential molecular predictor for ovarian cancer patient's survival: targeting Clusterin improves response to paclitaxel. Journal of Experimental & Clinical Cancer Research: CR 2011, 30:113.
56. Henrich-Noack P., Prehn J.H., Krieglstein J. TGF-beta 1 protects hippocampal neurons against degeneration caused by transient global ischemia. Dose-esponse relationship and potential neuroprotective mechanisms. Stroke: A Journal of Cerebral Circulation 1996, 27:1609-1614. [discussion 1615].
57. Hollyfield J.G., Salomon R.G., Crabb J.W. Proteomic approaches to understanding age-related macular degeneration. Advances in Experimental Medicine and Biology 2003, 533:83-89.
58. Hoofnagle A.N., Wu M., Gosmanova A.K., Becker J.O., Wijsman E.M., Brunzell J.D., Kahn S.E., Knopp R.H., Lyons T.J., Heinecke J.W. Low clusterin levels in high-density lipoprotein associate with insulin resistance, obesity, and dyslipoproteinemia. Arteriosclerosis, Thrombosis, and Vascular Biology 2010, 30:2528-2534.
59. Ijsselstijn L., Dekker L.J., Koudstaal P.J., Hofman A., Sillevis Smitt P.A., Breteler M.M., Luider T.M. Serum clusterin levels are not increased in presymptomatic Alzheimer's disease. Journal of Proteome Research 2011, 10:2006-2010.
60. Imhof A., Charnay Y., Vallet P.G., Aronow B., Kovari E., French L.E., Bouras C., Giannakopoulos P. Sustained astrocytic clusterin expression improves remodeling after brain ischemia. Neurobiology of Disease 2006, 22:274-283.
61. Ishikawa T., Zhu B.L., Li D.R., Zhao D., Michiue T., Maeda H. Age-dependent increase of clusterin in the human pituitary gland. Legal Medicine (Tokyo) 2006, 8:28-33.
62. Itahana Y., Piens M., Sumida T., Fong S., Muschler J., Desprez P.Y. Regulation of clusterin expression in mammary epithelial cells. Experimental Cell Research 2007, 313:943-951.
63. Iwata A., Browne K.D., Chen X.H., Yuguchi T., Smith D.H. Traumatic brain injury induces biphasic upregulation of ApoE and ApoJ protein in rats. Journal of Neuroscience Research 2005, 82:103-114.
64. Jenne D.E., Lowin B., Peitsch M.C., Bottcher A., Schmitz G., Tschopp J. Clusterin (complement lysis inhibitor) forms a high density lipoprotein complex with apolipoprotein A-I in human plasma. The Journal of Biological Chemistry 1991, 266:11030-11036.
65. Jenne D.E., Tschopp J. Molecular structure and functional characterization of a human complement cytolysis inhibitor found in blood and seminal plasma: identity to sulfated glycoprotein 2, a constituent of rat testis fluid. Proceedings of the National Academy of Sciences of the United States of America 1989, 86:7123-7127.
66. Jin G., Howe P.H. Transforming growth factor beta regulates clusterin gene expression via modulation of transcription factor c-Fos. European Journal of Biochemistry/FEBS 1999, 263:534-542.
67. Johnson L.V., Forest D.L., Banna C.D., Radeke C.M., Maloney M.A., Hu J., Spencer C.N., Walker A.M., Tsie M.S., Bok D., Radeke M.J., Anderson D.H. Cell culture model that mimics drusen formation and triggers complement activation associated with age-related macular degeneration. Proceedings of the National Academy of Sciences of the United States of America 2011, 108:18277-18282.
68. Jomary C., Darrow R.M., Wong P., Organisciak D.T., Neal M.J., Jones S.E. Lack of causal relationship between clusterin expression and photoreceptor apoptosis in light-induced retinal degeneration. Journal of Neurochemistry 1999, 72:1923-1929.
69. Jun G., Naj A.C., Beecham G.W., Wang L.S., Buros J., Gallins P.J., Buxbaum J.D., Ertekin-Taner N., Fallin M.D., Friedland R., Inzelberg R., Kramer P., Rogaeva E., St George-Hyslop P., Cantwell L.B., Dombroski B.A., Saykin A.J., Reiman E.M., Bennett D.A., Morris J.C., Lunetta K.L., Martin E.R., Montine T.J., Goate A.M., Blacker D., Tsuang D.W., Beekly D., Cupples L.A., Hakonarson H., Kukull W., Foroud T.M., Haines J., Mayeux R., Farrer L.A., Pericak-Vance M.A., Schellenberg G.D. Meta-analysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Archives of Neurology 2010, 67:1473-1484.
70. Kamboh M.I., Minster R.L., Demirci F.Y., Ganguli M., Dekosky S.T., Lopez O.L., Barmada M.M. Association of CLU and PICALM variants with Alzheimer's disease. Neurobiology of Aging 2012, 33:518-521.
71. Kapron J.T., Hilliard G.M., Lakins J.N., Tenniswood M.P., West K.A., Carr S.A., Crabb J.W. Identification and characterization of glycosylation sites in human serum clusterin. Protein Science: A Publication of the Protein Society 1997, 6:2120-2133.
72. Kempster S., Collins M.E., Aronow B.J., Simmons M., Green R.B., Edington N. Clusterin shortens the incubation and alters the histopathology of bovine spongiform encephalopathy in mice. Neuroreport 2004, 15:1735-1738.
73. Kim J.H., Kim J.H., Jun H.O., Yu Y.S., Min B.H., Park K.H., Kim K.W. Protective effect of clusterin from oxidative stress-induced apoptosis in human retinal pigment epithelial cells. Investigative Ophthalmology & Visual Science 2010, 51:561-566.
74. Kim J.H., Kim J.H., Yu Y.S., Min B.H., Kim K.W. Protective effect of clusterin on blood-etinal barrier breakdown in diabetic retinopathy. Investigative Ophthalmology & Visual Science 2010, 51:1659-1665.
75. Kim N., Choi W.S. Proapoptotic role of nuclear clusterin in brain. Anatomy & Cell Biology 2011, 44:169-175.
76. Kim N., Han J.Y., Roh G.S., Kim H.J., Kang S.S., Cho G.J., Park J.Y., Choi W.S. Nuclear clusterin is associated with neuronal apoptosis in the developing rat brain upon ethanol exposure. Alcoholism, Clinical and Experimental Research 2012, 36:72-82.
77. Kirszbaum L., Sharpe J.A., Murphy B., d'Apice A.J., Classon B., Hudson P., Walker I.D. Molecular cloning and characterization of the novel, human complement-associated protein, SP-40,40: a link between the complement and reproductive systems. The EMBO Journal 1989, 8:711-718.
78. Kliger Y., Levy O., Oren A., Ashkenazy H., Tiran Z., Novik A., Rosenberg A., Amir A., Wool A., Toporik A., Schreiber E., Eshel D., Levine Z., Cohen Y., Nold-Petry C., Dinarello C.A., Borukhov I. Peptides modulating conformational changes in secreted chaperones: from in silico design to preclinical proof of concept. Proceedings of the National Academy of Sciences of the United States of America 2009, 106:13797-13801.
79. Klimaschewski L., Obermuller N., Witzgall R. Regulation of clusterin expression following spinal cord injury. Cell and Tissue Research 2001, 306:209-216.
80. Klock G., Baiersdorfer M., Koch-Brandt C. Chapter 7: cell protective functions of secretory Clusterin (sCLU). Advances in Cancer Research 2009, 104:115-138.
81. Komotar R.J., Kim G.H., Otten M.L., Hassid B., Mocco J., Sughrue M.E., Starke R.M., Mack W.J., Ducruet A.F., Merkow M.B., Garrett M.C., Connolly E.S. The role of complement in stroke therapy. Advances in Experimental Medicine and Biology 2008, 632:23-33.
82. Krumbiegel M., Pasutto F., Mardin C.Y., Weisschuh N., Paoli D., Gramer E., Zenkel M., Weber B.H., Kruse F.E., Schlotzer-Schrehardt U., Reis A. Exploring functional candidate genes for genetic association in German patients with pseudoexfoliation syndrome and pseudoexfoliation glaucoma. Investigative Ophthalmology & Visual Science 2009, 50:2796-2801.
83. Kujiraoka T., Hattori H., Miwa Y., Ishihara M., Ueno T., Ishii J., Tsuji M., Iwasaki T., Sasaguri Y., Fujioka T., Saito S., Tsushima M., Maruyama T., Miller I.P., Miller N.E., Egashira T. Serum apolipoprotein j in health, coronary heart disease and type 2 diabetes mellitus. Journal of Atherosclerosis and Thrombosis 2006, 13:314-322.
84. Lakins J.N., Poon S., Easterbrook-Smith S.B., Carver J.A., Tenniswood M.P., Wilson M.R. Evidence that clusterin has discrete chaperone and ligand binding sites. Biochemistry 2002, 41:282-291.
85. Lambert J.C., Heath S., Even G., Campion D., Sleegers K., Hiltunen M., Combarros O., Zelenika D., Bullido M.J., Tavernier B., Letenneur L., Bettens K., Berr C., Pasquier F., Fievet N., Barberger-Gateau P., Engelborghs S., De Deyn P., Mateo I., Franck A., Helisalmi S., Porcellini E., Hanon O., de Pancorbo M.M., Lendon C., Dufouil C., Jaillard C., Leveillard T., Alvarez V., Bosco P., Mancuso M., Panza F., Nacmias B., Bossu P., Piccardi P., Annoni G., Seripa D., Galimberti D., Hannequin D., Licastro F., Soininen H., Ritchie K., Blanche H., Dartigues J.F., Tzourio C., Gut I., Van Broeckhoven C., Alperovitch A., Lathrop M., Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nature Genetics 2009, 41:1094-1099.
86. Lamoureux L., Simon S.L., Plews M., Stobart M., Groschup M., Czub S., Graham C., Knox J.D. Analysis of clusterin glycoforms in the urine of BSE-infected Fleckvieh-Simmental cows. Journal of Toxicology and Environmental Health. Part A 2011, 74:138-145.
87. Lancaster T.M., Baird A., Wolf C., Jackson M.C., Johnston S.J., Donev R., Thome J., Linden D.E. Neural hyperactivation in carriers of the Alzheimer's risk variant on the clusterin gene. European Neuropsychopharmacology: The Journal of the European College of Neuropsychopharmacology 2011, 21:880-884.
88. Laskin J.J., Nicholas G., Lee C., Gitlitz B., Vincent M., Cormier Y., Stephenson J., Ung Y., Sanborn R., Pressnail B., Nugent F., Nemunaitis J., Gleave M.E., Murray N., Hao D. Phase I/II trial of custirsen (OGX-011), an inhibitor of clusterin, in combination with a gemcitabine and platinum regimen in patients with previously untreated advanced non-small cell lung cancer. Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer 2012, 7:579-586.
89. Lee K.B., Jeon J.H., Choi I., Kwon O.Y., Yu K., You K.H. Clusterin, a novel modulator of TGF-beta signaling, is involved in Smad2/3 stability. Biochemical and Biophysical Research Communications 2008, 366:905-909.
90. Lee S., Hong S.W., Min B.H., Shim Y.J., Lee K.U., Lee I.K., Bendayan M., Aronow B.J., Park I.S. Essential role of clusterin in pancreas regeneration. Developmental Dynamics: An Official Publication of the American Association of Anatomists 2011, 240:605-615.
91. Lee Y.N., Shim Y.J., Kang B.H., Park J.J., Min B.H. Over-expression of human clusterin increases stress resistance and extends lifespan in Drosophila melanogaster. Biochemical and Biophysical Research Communications 2012, 420:851-856.
92. Lenferink A.E., Cantin C., Nantel A., Wang E., Durocher Y., Banville M., Paul-Roc B., Marcil A., Wilson M.R., O'Connor-McCourt M.D. Transcriptome profiling of a TGF-beta-induced epithelial-to-mesenchymal transition reveals extracellular clusterin as a target for therapeutic antibodies. Oncogene 2010, 29:831-844.
93. Leskov K.S., Araki S., Lavik J.P., Gomez J.A., Gama V., Gonos E.S., Trougakos I.P., Matsuyama S., Boothman D.A. CRM1 protein-mediated regulation of nuclear clusterin (nCLU), an ionizing radiation-stimulated, Bax-dependent pro-death factor. The Journal of Biological Chemistry 2011, 286:40083-40090.
94. Lin Y.L., Chen S.Y., Lai L.C., Chen J.H., Yang S.Y., Huang Y.L., Chen T.F., Sun Y., Wen L.L., Yip P.K., Chu Y.M., Chen W.J., Chen Y.C. Genetic polymorphisms of clusterin gene are associated with a decreased risk of Alzheimer's disease. European Journal of Epidemiology 2012, 27:73-77.
95. Liu L., Tornqvist E., Mattsson P., Eriksson N.P., Persson J.K., Morgan B.P., Aldskogius H., Svensson M. Complement and clusterin in the spinal cord dorsal horn and gracile nucleus following sciatic nerve injury in the adult rat. Neuroscience 1995, 68:167-179.
96. Liu T., Liu P.Y., Tee A.E., Haber M., Norris M.D., Gleave M.E., Marshall G.M. Over-expression of clusterin is a resistance factor to the anti-cancer effect of histone deacetylase inhibitors. European Journal of Cancer 2009, 45:1846-1854.
97. Ma J.F., Liu L.H., Zhang Y., Wang Y., Deng Y.L., Huang Y., Wang G., Xu W., Cui P.J., Fei Q.Z., Ding J.Q., Tang H.D., Chen S.D. Association study of clusterin polymorphism rs11136000 with late onset Alzheimer's disease in Chinese Han population. American Journal of Alzheimer's Disease and Other Dementias 2011, 26:627-630.
98. Martin-Rehrmann M.D., Hoe H.S., Capuani E.M., Rebeck G.W. Association of apolipoprotein J-positive beta-amyloid plaques with dystrophic neurites in Alzheimer's disease brain. Neurotoxicity Research 2005, 7:231-242.
99. Materia S., Cater M.A., Klomp L.W., Mercer J.F., La Fontaine S. Clusterin (apolipoprotein J), a molecular chaperone that facilitates degradation of the copper-ATPases ATP7A and ATP7B. The Journal of Biological Chemistry 2011, 286:10073-10083.
100. Matsubara E. Apolipoprotein J and Alzheimer's amyloid beta solubility. Japanese Journal of Geriatrics 1999, 36:110-115.
101. McGeer P.L., Kawamata T., Walker D.G. Distribution of clusterin in Alzheimer brain tissue. Brain Research 1992, 579:337-341.
102. McHattie S., Wells G.A., Bee J., Edington N. Clusterin in bovine spongiform encephalopathy (BSE). Journal of Comparative Pathology 1999, 121:159-171.
103. Mengel-From J., Christensen K., McGue M., Christiansen L. Genetic variations in the CLU and PICALM genes are associated with cognitive function in the oldest old. Neurobiology of Aging 2011, 32. 554 e557-511.
104. Michel D., Chatelain G., North S., Brun G. Stress-induced transcription of the clusterin/apoJ gene. The Biochemical Journal 1997, 328(Pt 1):45-50.
105. Miura Y., Sato Y., Arai Y., Abe Y., Takayama M., Toda T., Hirose N., Endo T. Proteomic analysis of plasma proteins in Japanese semisuper centenarians. Experimental Gerontology 2011, 46:81-85.
106. Morgan T.E., Laping N.J., Rozovsky I., Oda T., Hogan T.H., Finch C.E., Pasinetti G.M. Clusterin expression by astrocytes is influenced by transforming growth factor beta 1 and heterotypic cell interactions. Journal of Neuroimmunology 1995, 58:101-110.
107. Morgan T.E., Xie Z., Goldsmith S., Yoshida T., Lanzrein A.S., Stone D., Rozovsky I., Perry G., Smith M.A., Finch C.E. The mosaic of brain glial hyperactivity during normal ageing and its attenuation by food restriction. Neuroscience 1999, 89:687-699.
108. Narayan P., Orte A., Clarke R.W., Bolognesi B., Hook S., Ganzinger K.A., Meehan S., Wilson M.R., Dobson C.M., Klenerman D. The extracellular chaperone clusterin sequesters oligomeric forms of the amyloid-beta(1-40) peptide. Nature Structural & Molecular Biology 2012, 19:79-83.
109. Nilselid A.M., Davidsson P., Nagga K., Andreasen N., Fredman P., Blennow K. Clusterin in cerebrospinal fluid: analysis of carbohydrates and quantification of native and glycosylated forms. Neurochemistry International 2006, 48:718-728.
110. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Clusterin: a forgotten player in Alzheimer's disease. Brain Research Reviews 2009, 61:89-104.
111. Nuutinen T., Suuronen T., Kauppinen A., Salminen A. Valproic acid stimulates clusterin expression in human astrocytes: implications for Alzheimer's disease. Neuroscience Letters 2010, 475:64-68.
112. Nuutinen T., Suuronen T., Kyrylenko S., Huuskonen J., Salminen A. Induction of clusterin/apoJ expression by histone deacetylase inhibitors in neural cells. Neurochemistry International 2005, 47:528-538.
113. O'Bryan M.K., Cheema S.S., Bartlett P.F., Murphy B.F., Pearse M.J. Clusterin levels increase during neuronal development. Journal of Neurobiology 1993, 24:421-432.
114. Oda T., Pasinetti G.M., Osterburg H.H., Anderson C., Johnson S.A., Finch C.E. Purification and characterization of brain clusterin. Biochemical and Biophysical Research Communications 1994, 204:1131-1136.
115. Ohlsson M., Bellander B.M., Langmoen I.A., Svensson M. Complement activation following optic nerve crush in the adult rat. Journal of Neurotrauma 2003, 20:895-904.
116. Page K.J., Hollister R.D., Hyman B.T. Dissociation of apolipoprotein and apolipoprotein receptor response to lesion in the rat brain: an in situ hybridization study. Neuroscience 1998, 85:1161-1171.
117. Pasinetti G.M., Johnson S.A., Oda T., Rozovsky I., Finch C.E. Clusterin (SGP-2): a multifunctional glycoprotein with regional expression in astrocytes and neurons of the adult rat brain. The Journal of Comparative Neurology 1994, 339:387-400.
118. Patel N.V., Wei M., Wong A., Finch C.E., Morgan T.E. Progressive changes in regulation of apolipoproteins E and J in glial cultures during postnatal development and aging. Neuroscience Letters 2004, 371:199-204.
119. Perl D.P., Olanow C.W., Calne D. Alzheimer's disease and Parkinson's disease: distinct entities or extremes of a spectrum of neurodegeneration?. Annals of Neurology 1998, 44:S19-S31.
120. Polihronis M., Paizis K., Carter G., Sedal L., Murphy B. Elevation of human cerebrospinal fluid clusterin concentration is associated with acute neuropathology. Journal of the Neurological Sciences 1993, 115:230-233.
121. Prikrylova Vranova H., Mares J., Nevrly M., Stejskal D., Zapletalova J., Hlustik P., Kanovsky P. CSF markers of neurodegeneration in Parkinson's disease. Journal of Neural Transmission 2010, 117:1177-1181.
122. Qian Y.R., Lee M.J., Hwang S., Kook J.H., Kim J.K., Bae C.S. Neuroprotection by valproic Acid in mouse models of permanent and transient focal cerebral ischemia. The Korean Journal of Physiology & Pharmacology: Official Journal of the Korean Physiological Society and the Korean Society of Pharmacology 2010, 14:435-440.
123. Ranney M.K., Ahmed I.S., Potts K.R., Craven R.J. Multiple pathways regulating the anti-apoptotic protein clusterin in breast cancer. Biochimica et Biophysica Acta 2007, 1772:1103-1111.
124. Reddy K.B., Jin G., Karode M.C., Harmony J.A., Howe P.H. Transforming growth factor beta (TGF beta)-induced nuclear localization of apolipoprotein J/clusterin in epithelial cells. Biochemistry 1996, 35:6157-6163.
125. Reddy K.B., Karode M.C., Harmony A.K., Howe P.H. Interaction of transforming growth factor beta receptors with apolipoprotein J/clusterin. Biochemistry 1996, 35:309-314.
126. Reeder D.J., Stuart W.D., Witte D.P., Brown T.L., Harmony J.A. Local synthesis of apolipoprotein J in the eye. Experimental Eye Research 1995, 60:495-504.
127. Rithidech K.N., Honikel L., Milazzo M., Madigan D., Troxell R., Krupp L.B. Protein expression profiles in pediatric multiple sclerosis: potential biomarkers. Multiple Sclerosis 2009, 15:455-464.
128. Roussa E., von Bohlen und Halbach O., Krieglstein K. TGF-beta in dopamine neuron development, maintenance and neuroprotection. Advances in Experimental Medicine and Biology 2009, 651:81-90.
129. Saad F., Hotte S., North S., Eigl B., Chi K., Czaykowski P., Wood L., Pollak M., Berry S., Lattouf J.B., Mukherjee S.D., Gleave M., Winquist E. Randomized phase II trial of Custirsen (OGX-011) in combination with docetaxel or mitoxantrone as second-line therapy in patients with metastatic castrate-resistant prostate cancer progressing after first-line docetaxel: CUOG trial P-06c. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2011, 17:5765-5773.
130. Sasaki K., Doh-ura K., Ironside J., Mabbott N., Iwaki T. Clusterin expression in follicular dendritic cells associated with prion protein accumulation. The Journal of Pathology 2006, 209:484-491.
131. Sasaki K., Doh-ura K., Ironside J.W., Iwaki T. Increased clusterin (apolipoprotein J) expression in human and mouse brains infected with transmissible spongiform encephalopathies. Acta Neuropathologica 2002, 103:199-208.
132. Sasaki K., Doh-ura K., Wakisaka Y., Iwaki T., Clusterin/apolipoprotein Acta Neuropathologica 2002, 104:225-230.
133. Savkovic V., Gantzer H., Reiser U., Selig L., Gaiser S., Sack U., Kloppel G., Mossner J., Keim V., Horn F., Bodeker H. Clusterin is protective in pancreatitis through anti-apoptotic and anti-inflammatory properties. Biochemical and Biophysical Research Communications 2007, 356:431-437.
134. Schlotzer-Schrehardt U. Genetics and genomics of pseudoexfoliation syndrome/glaucoma. Middle East African Journal of Ophthalmology 2011, 18:30-36.
135. Schmitt-Ulms G., Hansen K., Liu J., Cowdrey C., Yang J., DeArmond S.J., Cohen F.E., Prusiner S.B., Baldwin M.A. Time-controlled transcardiac perfusion cross-linking for the study of protein interactions in complex tissues. Nature Biotechnology 2004, 22:724-731.
136. Schrijvers E.M., Koudstaal P.J., Hofman A., Breteler M.M. Plasma clusterin and the risk of Alzheimer disease. JAMA: The Journal of the American Medical Association 2011, 305:1322-1326.
137. Serrano A., Redondo M., Tellez T., Castro-Vega I., Roldan M.J., Mendez R., Rueda A., Jimenez E. Regulation of clusterin expression in human cancer via DNA methylation. Tumour Biology: The Journal of the International Society for Oncodevelopmental Biology and Medicine 2009, 30:286-291.
138. Shanmugaratnam J., Berg E., Kimerer L., Johnson R.J., Amaratunga A., Schreiber B.M., Fine R.E. Retinal Muller glia secrete apolipoproteins E and J which are efficiently assembled into lipoprotein particles. Brain research. Molecular Brain Research 1997, 50:113-120.
139. Shannan B., Seifert M., Boothman D.A., Tilgen W., Reichrath J. Clusterin over-expression modulates proapoptotic and antiproliferative effects of 1,25(OH)2D3 in prostate cancer cells in vitro. The Journal of Steroid Biochemistry and Molecular Biology 2007, 103:721-725.
140. Shannan B., Seifert M., Leskov K., Willis J., Boothman D., Tilgen W., Reichrath J. Challenge and promise: roles for clusterin in pathogenesis, progression and therapy of cancer. Cell Death and Differentiation 2006, 13:12-19.
141. Shin J.K., Han K.A., Kang M.Y., Kim Y.S., Park J.K., Choi W.J., Lee S.A., Lee J.H., Choi W.S., Paik W.Y. Expression of clusterin in normal and preeclamptic placentas. The Journal of Obstetrics and Gynaecology Research 2008, 34:473-479.
142. Shiota M., Zoubeidi A., Kumano M., Beraldi E., Naito S., Nelson C.C., Sorensen P.H., Gleave M.E. Clusterin is a critical downstream mediator of stress-induced YB-1 transactivation in prostate cancer. Molecular Cancer Research: MCR 2011, 9:1755-1766.
143. Sihlbom C., Davidsson P., Sjogren M., Wahlund L.O., Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochemical Research 2008, 33:1332-1340.
144. Stewart E.M., Aquilina J.A., Easterbrook-Smith S.B., Murphy-Durland D., Jacobsen C., Moestrup S., Wilson M.R. Effects of glycosylation on the structure and function of the extracellular chaperone clusterin. Biochemistry 2007, 46:1412-1422.
145. Stoop M.P., Dekker L.J., Titulaer M.K., Burgers P.C., Sillevis Smitt P.A., Luider T.M., Hintzen R.Q. Multiple sclerosis-related proteins identified in cerebrospinal fluid by advanced mass spectrometry. Proteomics 2008, 8:1576-1585.
146. Storini C., Rossi E., Marrella V., Distaso M., Veerhuis R., Vergani C., Bergamaschini L., De Simoni M.G. C1-inhibitor protects against brain ischemia-reperfusion injury via inhibition of cell recruitment and inflammation. Neurobiology of Disease 2005, 19:10-17.
147. Strocchi P., Rauzi F., Cevolani D. Neuronal loss up-regulates clusterin mRNA in living neurons and glial cells in the rat brain. Neuroreport 1999, 10:1789-1792.
148. Sturgill G.M., Pauer G.J., Bala E., Simpson E., Yaniglos S.S., Crabb J.W., Hollyfield J.G., Lewis H., Peachey N.S., Hagstrom S.A. Mutation screen of the cone-specific gene, CLUL1, in 376 patients with age-related macular degeneration. Ophthalmic Genetics 2006, 27:151-155.
149. Suuronen T., Nuutinen T., Ryhanen T., Kaarniranta K., Salminen A. Epigenetic regulation of clusterin/apolipoprotein J expression in retinal pigment epithelial cells. Biochemical and Biophysical Research Communications 2007, 357:397-401.
150. Takamaru Y. Analysis of the 80kDa antigen in senile plaque amyloid. Hokkaido igaku zasshi 1994, 69:191-201.
151. Ten V.S., Yao J., Ratner V., Sosunov S., Fraser D.A., Botto M., Sivasankar B., Morgan B.P., Silverstein S., Stark R., Polin R., Vannucci S.J., Pinsky D., Starkov A.A. Complement component c1q mediates mitochondria-driven oxidative stress in neonatal hypoxic-ischemic brain injury. The Journal of Neuroscience: The Official Journal of the Society for Neuroscience 2010, 30:2077-2087.
152. Thambisetty M. Do extracellular chaperone proteins in plasma have potential as Alzheimer's disease biomarkers?. Biomarkers in Medicine 2010, 4:831-834.
153. Thambisetty M., An Y., Kinsey A., Koka D., Saleem M., Guntert A., Kraut M., Ferrucci L., Davatzikos C., Lovestone S., Resnick S.M. Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. NeuroImage 2012, 59:212-217.
154. Thambisetty M., Simmons A., Velayudhan L., Hye A., Campbell J., Zhang Y., Wahlund L.O., Westman E., Kinsey A., Guntert A., Proitsi P., Powell J., Causevic M., Killick R., Lunnon K., Lynham S., Broadstock M., Choudhry F., Howlett D.R., Williams R.J., Sharp S.I., Mitchelmore C., Tunnard C., Leung R., Foy C., O'Brien D., Breen G., Furney S.J., Ward M., Kloszewska I., Mecocci P., Soininen H., Tsolaki M., Vellas B., Hodges A., Murphy D.G., Parkins S., Richardson J.C., Resnick S.M., Ferrucci L., Wong D.F., Zhou Y., Muehlboeck S., Evans A., Francis P.T., Spenger C., Lovestone S. Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Archives of General Psychiatry 2010, 67:739-748.
155. Van Beek J., Chan P., Bernaudin M., Petit E., MacKenzie E.T., Fontaine M. Glial responses, clusterin, and complement in permanent focal cerebral ischemia in the mouse. Glia 2000, 31:39-50.
156. Verbrugghe P., Kujala P., Waelput W., Peters P.J., Cuvelier C.A. Clusterin in human gut-associated lymphoid tissue, tonsils, and adenoids: localization to M cells and follicular dendritic cells. Histochemistry and Cell Biology 2008, 129:311-320.
157. Wang L., Clark M.E., Crossman D.K., Kojima K., Messinger J.D., Mobley J.A., Curcio C.A. Abundant lipid and protein components of drusen. PLoS One 2010, 5:e10329.
158. Wehrli P., Charnay Y., Vallet P., Zhu G., Harmony J., Aronow B., Tschopp J., Bouras C., Viard-Leveugle I., French L.E., Giannakopoulos P. Inhibition of post-ischemic brain injury by clusterin overexpression. Nature Medicine 2001, 7:977-979.
159. White F., Nicoll J.A., Horsburgh K. Alterations in ApoE and ApoJ in relation to degeneration and regeneration in a mouse model of entorhinal cortex lesion. Experimental Neurology 2001, 169:307-318.
160. Wicher G., Fex-Svenningsen A., Velsecchi I., Charnay Y., Aldskogius H. Extracellular clusterin promotes neuronal network complexity in vitro. Neuroreport 2008, 19:1487-1491.
161. Wicher G.K., Aldskogius H. Adult motor neurons show increased susceptibility to axotomy-induced death in mice lacking clusterin. The European Journal of Neuroscience 2005, 21:2024-2028.
162. Wilson M.R., Yerbury J.J., Poon S. Potential roles of abundant extracellular chaperones in the control of amyloid formation and toxicity. Molecular BioSystems 2008, 4:42-52.
163. Wong P., Pfeffer B.A., Bernstein S.L., Chambers M.L., Chader G.J., Zakeri Z.F., Wu Y.Q., Wilson M.R., Becerra S.P. Clusterin protein diversity in the primate eye. Molecular Vision 2000, 6:184-191.
164. Wyatt A.R., Yerbury J.J., Berghofer P., Greguric I., Katsifis A., Dobson C.M., Wilson M.R. Clusterin facilitates in vivo clearance of extracellular misfolded proteins. Cellular and Molecular Life Sciences: CMLS 2011, 68:3919-3931.
165. Xing Y.Y., Yu J.T., Cui W.Z., Zhong X.L., Wu Z.C., Zhang Q., Tan L. Blood clusterin levels, rs9331888 polymorphism, and the risk of Alzheimer's disease. Journal of Alzheimer's Disease: JAD 2012.
166. Xu F., Karnaukhova E., Vostal J.G. Human cellular prion protein interacts directly with clusterin protein. Biochimica et Biophysica Acta 2008, 1782:615-620.
167. Xu Q., Li Y., Cyras C., Sanan D.A., Cordell B. Isolation and characterization of apolipoproteins from murine microglia. Identification of a low density lipoprotein-like apolipoprotein J-rich but E-poor spherical particle. The Journal of Biological Chemistry 2000, 275:31770-31777.
168. Xue H.Y., Wong H.L. Targeting megalin to enhance delivery of anti-clusterin small-interfering RNA nanomedicine to chemo-treated breast cancer. European Journal of Pharmaceutics and Biopharmaceutics: Official Journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 2010, 15:115-121.
169. Yerbury J.J., Wilson M.R. Extracellular chaperones modulate the effects of Alzheimer's patient cerebrospinal fluid on Abeta(1-42) toxicity and uptake. Cell Stress & Chaperones 2010, 15:115-121.
170. Yu J.T., Tan L. The role of clusterin in Alzheimer's disease: pathways, pathogenesis, and therapy. Molecular Neurobiology 2012, 45:314-326.
171. Zhan L., Wang T., Li W., Xu Z.C., Sun W., Xu E. Activation of Akt/FoxO signaling pathway contributes to induction of neuroprotection against transient global cerebral ischemia by hypoxic pre-conditioning in adult rats. Journal of Neurochemistry 2010, 114:897-908.
172. Zhang Q., Ray K., Acland G.M., Czarnecki J.M., Aguirre G.D. Molecular cloning, characterization and expression of a novel retinal clusterin-like protein cDNA. Gene 2000, 243:151-160.
173. Zhong B., Sallman D.A., Gilvary D.L., Pernazza D., Sahakian E., Fritz D., Cheng J.Q., Trougakos I., Wei S., Djeu J.Y. Induction of clusterin by AKT-role in cytoprotection against docetaxel in prostate tumor cells. Molecular Cancer Therapeutics 2010, 9:1831-1841.
174. Zhou M., Shen D., Head J.E., Chew E.Y., Chevez-Barrios P., Green W.R., Chan C.C. Ocular clusterin expression in Von Hippel-Lindau disease. Molecular Vision 2007, 13:2129-2136.
175. Zlokovic B.V., Martel C.L., Mackic J.B., Matsubara E., Wisniewski T., McComb J.G., Frangione B., Ghiso J. Brain uptake of circulating apolipoproteins J and E complexed to Alzheimer's amyloid beta. Biochemical and Biophysical Research Communications 1994, 205:1431-1437.
176. Zlokovic B.V., Martel C.L., Matsubara E., McComb J.G., Zheng G., McCluskey R.T., Frangione B., Ghiso J. Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers. Proceedings of the National Academy of Sciences of the United States of America 1996, 93:4229-4234.
177. Zoubeidi A., Chi K., Gleave M. Targeting the cytoprotective chaperone, clusterin, for treatment of advanced cancer. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2010, 16:1088-1093.